MCID: ACN001
MIFTS: 52

Acinar Cell Carcinoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Acinar Cell Carcinoma

MalaCards integrated aliases for Acinar Cell Carcinoma:

Name: Acinar Cell Carcinoma 12 14 69
Acinic Cell Carcinoma 12 49
Carcinoma, Acinar Cell 41
Carcinoma Acinar Cell 51
Acinic Cell Tumor 49
Acinar Cell Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3025
MeSH 41 D018267
NCIt 46 C3768
SNOMED-CT 64 45410002

Summaries for Acinar Cell Carcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from spindle cells and/or derives from giant cells.

MalaCards based summary : Acinar Cell Carcinoma, also known as acinic cell carcinoma, is related to pancreatic acinar cell adenocarcinoma and pancreatoblastoma. An important gene associated with Acinar Cell Carcinoma is CHGA (Chromogranin A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Fluorouracil and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, salivary gland and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acinar Cell Carcinoma

Diseases related to Acinar Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 pancreatic acinar cell adenocarcinoma 32.6 AFP BCL10 CHGA
2 pancreatoblastoma 29.9 AFP CHGA SERPINA1
3 pancreas adenocarcinoma 29.1 BRCA2 CTNNB1 SMAD4 TP53
4 adenoma 28.9 APC CTNNB1 KRT7 SMAD4 TP53
5 pancreatic cancer 28.7 BRCA2 CHGA CTNNB1 SMAD4 TP53
6 gastric cancer 28.5 AFP APC CTNNB1 SMAD4 TP53
7 hepatocellular carcinoma 27.3 AFP APC CTNNB1 KRT7 SERPINA1 SMAD4
8 acinar cell carcinoma of pancreas 12.5
9 pancreatitis 10.8
10 uterine corpus serous adenocarcinoma 10.5 BRCA2 TP53
11 tetraploidy 10.5 BRCA2 TP53
12 familial colorectal cancer type x 10.4 BRCA2 SMAD4
13 hyperplastic polyposis syndrome 10.4 APC TP53
14 cellular ependymoma 10.4 CHGA TP53
15 fallopian tube adenocarcinoma 10.4 BRCA2 TP53
16 olfactory groove meningioma 10.4 CHGA TP53
17 synchronous bilateral breast carcinoma 10.4 BRCA2 TP53
18 atypical follicular adenoma 10.4 CHGA TP53
19 anal squamous cell carcinoma 10.4 APC TP53
20 adult teratoma 10.4 AFP CHGA
21 anterior cranial fossa meningioma 10.4 CHGA TP53
22 sclerosing hepatic carcinoma 10.4 AFP CHGA
23 small cell neuroendocrine carcinoma 10.4 CHGA TP53
24 gastric lymphoma 10.3 BCL10 TP53
25 urethral benign neoplasm 10.3 CHGA SMAD4
26 pulmonary blastoma 10.3 CHGA TP53
27 pleomorphic xanthoastrocytoma 10.3 CHGA TP53
28 vaginal benign neoplasm 10.3 CHGA KRT7
29 ovarian large-cell neuroendocrine carcinoma 10.3 CHGA KRT7
30 vaginal adenoma 10.3 CHGA KRT7
31 vaginal tubulovillous adenoma 10.3 CHGA KRT7
32 liver sarcoma 10.3 AFP CHGA
33 small cell carcinoma of the bladder 10.3 CHGA KRT7
34 malignant spiradenoma 10.3 KRT7 TP53
35 vulvar intraepithelial neoplasia 10.3 KRT7 TP53
36 panniculitis 10.3
37 scrotal carcinoma 10.3 AFP TP53
38 pancreatic serous cystadenoma 10.3 CHGA KRT7
39 eccrine sweat gland neoplasm 10.3 KRT7 TP53
40 mature teratoma 10.3 AFP TP53
41 orofaciodigital syndrome viii 10.3 AFP BCL10
42 alpha-fetoprotein deficiency 10.3
43 bladder carcinoma in situ 10.3 KRT7 TP53
44 colloid carcinoma of the pancreas 10.2 BRCA2 SMAD4
45 papillary serous adenocarcinoma 10.2 KRT7 TP53
46 acinar cell cystadenocarcinoma 10.2 CHGA SERPINA1
47 nasal cavity adenocarcinoma 10.2 KRT7 TP53
48 intrahepatic bile duct adenoma 10.2 AFP KRT7
49 cowden disease 10.2 BRCA2 CHGA SMAD4
50 mutyh-associated polyposis 10.2 APC SMAD4 TP53

Graphical network of the top 20 diseases related to Acinar Cell Carcinoma:



Diseases related to Acinar Cell Carcinoma

Symptoms & Phenotypes for Acinar Cell Carcinoma

GenomeRNAi Phenotypes related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.98 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.98 SMAD4 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.98 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.98 AFP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.98 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.98 APC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.98 KRT7
8 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.98 APC CTNNB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.98 AFP KRT7 APC
10 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.98 CTNNB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.98 APC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.98 SMAD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.98 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.98 AFP APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.98 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.98 SMAD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.98 SMAD4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.98 CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.98 CTNNB1 APC
20 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.98 SMAD4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.98 AFP
22 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.98 CTNNB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.98 CTNNB1 SMAD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.98 CTNNB1 KRT7 APC SMAD4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.98 CTNNB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.98 SMAD4
27 Decreased viability in esophageal squamous lineage GR00235-A 9.61 AFP APC KRT7 SMAD4 BCL10 BRCA2

MGI Mouse Phenotypes related to Acinar Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 SMAD4 TP53 CHGA AFP CTNNB1 APC
2 cellular MP:0005384 10.08 SMAD4 TP53 CTNNB1 APC BCL10 ETV6
3 homeostasis/metabolism MP:0005376 10.07 SMAD4 TP53 CHGA AFP CTNNB1 APC
4 embryo MP:0005380 9.98 SMAD4 TP53 CTNNB1 APC BCL10 ETV6
5 digestive/alimentary MP:0005381 9.93 SMAD4 TP53 CTNNB1 APC ETV6 BRCA2
6 mortality/aging MP:0010768 9.91 SMAD4 TP53 CHGA AFP CTNNB1 APC
7 limbs/digits/tail MP:0005371 9.72 SMAD4 TP53 BRCA2 CTNNB1 APC
8 neoplasm MP:0002006 9.7 SMAD4 TP53 AFP CTNNB1 APC ETV6
9 renal/urinary system MP:0005367 9.43 SMAD4 TP53 CHGA CTNNB1 APC KRT7
10 reproductive system MP:0005389 9.23 SMAD4 TP53 CHGA AFP CTNNB1 APC

Drugs & Therapeutics for Acinar Cell Carcinoma

Drugs for Acinar Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
4
Pancrelipase Approved, Investigational Phase 3,Phase 2,Phase 1 53608-75-6
5
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
6
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
13 Liver Extracts Phase 3,Phase 1
14 Antidotes Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 3,Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
18 Antiviral Agents Phase 3,Phase 2,Phase 1
19 Calcium, Dietary Phase 3,Phase 2,Phase 1
20 Micronutrients Phase 3,Phase 2,Phase 1
21 pancreatin Phase 3,Phase 2,Phase 1
22 Protective Agents Phase 3,Phase 2,Phase 1
23 Trace Elements Phase 3,Phase 2,Phase 1
24 Vitamin B Complex Phase 3,Phase 2,Phase 1
25 Vitamins Phase 3,Phase 2,Phase 1
26 Antidepressive Agents Phase 3
27 Antidepressive Agents, Tricyclic Phase 3
28 Histamine Antagonists Phase 3
29
Histamine Phosphate Phase 3 51-74-1 65513
30 Neurotransmitter Agents Phase 3
31 Psychotropic Drugs Phase 3
32 Adjuvants, Anesthesia Phase 3
33 Analgesics Phase 3
34 Analgesics, Opioid Phase 3
35 Anesthetics Phase 3
36 Anesthetics, General Phase 3
37 Anesthetics, Intravenous Phase 3
38 Central Nervous System Depressants Phase 3
39 Narcotics Phase 3
40 Peripheral Nervous System Agents Phase 3
41 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
42
Erlotinib Hydrochloride Phase 3,Phase 1 183319-69-9 176871
43 Cola Nutraceutical Phase 3
44 Folate Nutraceutical Phase 3,Phase 2,Phase 1
45 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
46
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
47
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
48
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show all 46)

# Name Status NCT ID Phase Drugs
1 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
2 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
5 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
6 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
7 Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer Completed NCT00416793 Phase 2 bortezomib;carboplatin
8 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
9 Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Completed NCT00397787 Phase 2 sunitinib malate
10 Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Completed NCT00085371 Phase 2 triapine
11 Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Completed NCT00031694 Phase 2 paclitaxel;bryostatin 1
12 Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Completed NCT01234935 Phase 2 dasatinib;gemcitabine hydrochloride
13 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
14 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
15 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
16 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
17 Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer Recruiting NCT02047474 Phase 2 oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
18 Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Active, not recruiting NCT01666730 Phase 2 metformin hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
19 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Active, not recruiting NCT00859937 Phase 2 dasatinib
20 Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Suspended NCT02178436 Phase 1, Phase 2 gemcitabine hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation;selinexor
21 Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer Terminated NCT00967291 Phase 2 ifosfamide;mitomycin C
22 Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Terminated NCT00126607 Phase 2
23 Title XELOX FOR SALIVARY GLAND CANCERS Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
24 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
25 CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT01839981 Phase 1 6,8-bis(benzylthio)octanoic acid
26 Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride Completed NCT00981162 Phase 1 sorafenib tosylate;everolimus
27 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1 systemic chemotherapy
28 Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Active, not recruiting NCT00669734 Phase 1
29 Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer Active, not recruiting NCT01770132 Phase 1 porfimer sodium;gemcitabine hydrochloride
30 CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting NCT01835041 Phase 1 6,8-bis(benzylthio)octanoic acid;oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
31 GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT00878163 Phase 1 Erlotinib Hydrochloride;Gemcitabine Hydrochloride;Vismodegib
32 Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Active, not recruiting NCT01924260 Phase 1 alisertib;gemcitabine
33 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
34 Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Suspended NCT01537107 Phase 1 vismodegib;sirolimus
35 Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Terminated NCT01739439 Phase 1 gemcitabine hydrochloride
36 Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Withdrawn NCT01741597 Phase 1
37 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 cyclophosphamide
38 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
39 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Completed NCT00851253
40 Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema Completed NCT00828516
41 PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy Completed NCT00809016
42 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
43 Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Recruiting NCT02153450 Early Phase 1 metformin hydrochloride
44 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02757859
45 Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Active, not recruiting NCT01821612 oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine
46 Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study Terminated NCT00100321

Search NIH Clinical Center for Acinar Cell Carcinoma

Cochrane evidence based reviews: carcinoma, acinar cell

Genetic Tests for Acinar Cell Carcinoma

Anatomical Context for Acinar Cell Carcinoma

MalaCards organs/tissues related to Acinar Cell Carcinoma:

38
Pancreas, Salivary Gland, Liver, Brain, Lung, Breast, Skin

Publications for Acinar Cell Carcinoma

Articles related to Acinar Cell Carcinoma:

(show top 50) (show all 234)
# Title Authors Year
1
Curative distal pancreatectomy in patients with acinar cell carcinoma of pancreas diagnosed by endoscopic aspiration via esophago-jejunostomy: A successful case report. ( 29331883 )
2018
2
Murine Pancreatic Acinar Cell Carcinoma Growth Kinetics Are Independent of Dietary Vitamin D Deficiency or Supplementation. ( 28702373 )
2017
3
Primary pancreatic-type acinar cell carcinoma of the jejunum with tumor thrombus extending into the mesenteric venous system: a case report and literature review. ( 28662660 )
2017
4
Liver Metastases in Pancreatic Acinar Cell Carcinoma Treated with Selective Internal Radiation Therapy with Y-90 Resin Microspheres. ( 29158927 )
2017
5
A primary pure pancreatic-type acinar cell carcinoma of the stomach: a case report. ( 28103943 )
2017
6
Acinar Cell Carcinoma of the Pancreas: A Case Report. ( 28919629 )
2017
7
Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. ( 29184698 )
2017
8
Pancreatic acinar cell carcinoma with extensive tumor embolism at the trunk of portal vein and pancreatic intraductal infiltration. ( 28921102 )
2017
9
Acinar Cell Carcinoma in the Background of Chronic Calcific Pancreatitis. ( 28952013 )
2017
10
Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report. ( 28588779 )
2017
11
Bouveret syndrome and pancreatic acinar cell carcinoma. ( 28135730 )
2017
12
Establishment and characterization of a new human acinar cell carcinoma cell line, Faraz-ICR, from pancreas. ( 28215484 )
2017
13
Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma. ( 29052123 )
2017
14
Acinar cell carcinoma of the pancreas presenting as diffuse pancreatic enlargement: Two case reports and literature review. ( 28930825 )
2017
15
Acinar Cell Carcinoma of Pancreas: a Case Report and Review of Literature. ( 28660524 )
2017
16
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors. ( 29259370 )
2017
17
Severe panniculitis and polyarthritis caused by acinar cell carcinoma arising from an ectopic pancreas. ( 29167188 )
2017
18
Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. ( 28671770 )
2017
19
Metastatic pancreatic acinar cell carcinoma in a younger male with marked AFP production: A potential pitfall on fine needle aspiration biopsy. ( 27634114 )
2016
20
TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. ( 26586531 )
2016
21
Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. ( 27842335 )
2016
22
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen. ( 27857025 )
2016
23
Acinar cell carcinoma: a report of 19 cases with a brief review of the literature. ( 27352960 )
2016
24
Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. ( 27629876 )
2016
25
Cytological findings and BCL10 expression in pancreatic acinar cell carcinoma: A Case Report. ( 27860444 )
2016
26
Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver - case report and review of literature. ( 26895632 )
2016
27
Cytological findings of an ectopic pancreas of the stomach obtained at endoscopic ultrasound-guided fine needle aspiration, differential diagnosis from acinar cell carcinoma: a case report. ( 26786071 )
2016
28
A comparison study of pancreatic acinar cell carcinoma with ductal adenocarcinoma using computed tomography in Chinese patients. ( 27660464 )
2016
29
Pancreatic-type Acinar Cell Carcinoma of the Stomach Included in Multiple Primary Carcinomas. ( 27272797 )
2016
30
Pancreatic panniculitis as a paraneoplastic phenomenon of a pancreatic acinar cell carcinoma. ( 27112929 )
2016
31
Endoscopic ultrasound in the diagnosis of acinar cell carcinoma of the pancreas: contrast-enhanced endoscopic ultrasound, endoscopic ultrasound elastography, and pathological correlation. ( 27853750 )
2016
32
KRAS Mutations in Canine and Feline Pancreatic Acinar Cell Carcinoma. ( 27290644 )
2016
33
Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. ( 27165126 )
2016
34
Pancreatic Acinar Cell Carcinoma. ( 27403122 )
2016
35
Omental acinar cell carcinoma of pancreatic origin in a child: a clinicopathological rarity. ( 26694824 )
2016
36
Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. ( 25743105 )
2015
37
Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma. ( 26683340 )
2015
38
Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review. ( 25569665 )
2015
39
Acinar Cell Carcinoma of the Pancreas: Overview of Clinicopathologic Features and Insights into the Molecular Pathology. ( 26137463 )
2015
40
E-cadherin-negative acinar cell carcinoma of the pancreas: report of a case showing a solid pseudopapillary growth pattern. ( 25600280 )
2015
41
Expression of Albumin mRNA in Primary Hepatic Neoplasms and Acinar Cell Carcinoma. ( 26171921 )
2015
42
Ring around the ROSE: pancreatic acinar cell carcinoma diagnosed on site by EUS-FNA. ( 25805480 )
2015
43
ACINAR CELL CARCINOMA OF PANCREAS IN A CHILD: A RADIOLOGICAL PERSPECTIVE. ( 27004357 )
2015
44
Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma. ( 26600777 )
2015
45
Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. ( 26628966 )
2015
46
Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. ( 26456669 )
2015
47
Acinar Cell Carcinoma of the Pancreas: A Literature Review and Update. ( 26246707 )
2015
48
Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. ( 25959244 )
2015
49
Acinar cell carcinoma of exocrine pancreas in two horses. ( 24572625 )
2014
50
APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. ( 24590585 )
2014

Variations for Acinar Cell Carcinoma

Copy number variations for Acinar Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107120 19 1205798 1228434 Amplification LKB1 Acinar cell carcinoma
2 118120 17 7571720 7590868 Mutation TP53 Acinar cell carcinoma

Expression for Acinar Cell Carcinoma

Search GEO for disease gene expression data for Acinar Cell Carcinoma.

Pathways for Acinar Cell Carcinoma

Pathways related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 APC BRCA2 CTNNB1 SMAD4 TP53
2 12.55 APC BRCA2 CTNNB1 SMAD4 TP53
3
Show member pathways
12.47 APC BRCA2 CTNNB1 SMAD4 TP53
4
Show member pathways
12.28 APC CTNNB1 SMAD4 TP53
5 12.16 APC CTNNB1 SMAD4 TP53
6
Show member pathways
11.93 BRCA2 SMAD4 TP53
7 11.93 AFP APC CTNNB1 SMAD4
8 11.87 APC CTNNB1 SMAD4
9 11.84 CTNNB1 SMAD4 TP53
10 11.84 APC CTNNB1 SMAD4 TP53
11 11.82 AFP APC TP53
12 11.75 AFP APC CTNNB1 SMAD4
13 11.72 APC CTNNB1 TP53
14 11.64 BRCA2 CTNNB1 SMAD4 TP53
15 10.98 APC CTNNB1 SMAD4 TP53
16 10.96 APC CTNNB1
17 10.9 ETV6 SMAD4
18 10.79 APC CTNNB1
19 10.61 APC CTNNB1 SMAD4

GO Terms for Acinar Cell Carcinoma

Cellular components related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 AFP APC BCL10 BRCA2 CTNNB1 ETV6
2 centrosome GO:0005813 9.56 APC BRCA2 CTNNB1 SMAD4
3 beta-catenin destruction complex GO:0030877 9.16 APC CTNNB1
4 catenin complex GO:0016342 8.96 APC CTNNB1
5 Wnt signalosome GO:1990909 8.62 APC CTNNB1

Biological processes related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.71 APC CTNNB1 SMAD4 TP53
2 female gonad development GO:0008585 9.48 BRCA2 SMAD4
3 response to X-ray GO:0010165 9.46 BRCA2 TP53
4 cell proliferation GO:0008283 9.46 BRCA2 CTNNB1 SMAD4 TP53
5 beta-catenin destruction complex disassembly GO:1904886 9.43 APC CTNNB1
6 gastrulation with mouth forming second GO:0001702 9.37 CTNNB1 SMAD4
7 positive regulation of histone H3-K4 methylation GO:0051571 9.32 CTNNB1 SMAD4
8 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 BRCA2 TP53
9 positive regulation of apoptotic process GO:0043065 9.26 APC BCL10 CTNNB1 TP53
10 positive regulation of transcription, DNA-templated GO:0045893 9.02 BCL10 BRCA2 CTNNB1 SMAD4 TP53

Molecular functions related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.73 APC BCL10 BRCA2 SERPINA1 SMAD4 TP53
2 protein kinase binding GO:0019901 9.67 APC BCL10 CTNNB1 TP53
3 RNA polymerase II transcription factor binding GO:0001085 9.33 CTNNB1 SMAD4 TP53
4 I-SMAD binding GO:0070411 9.32 CTNNB1 SMAD4
5 protein C-terminus binding GO:0008022 9.26 BCL10 BRCA2 CTNNB1 TP53
6 protease binding GO:0002020 8.92 BCL10 BRCA2 SERPINA1 TP53

Sources for Acinar Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....